Signs, Symptoms, and Risk Factors
Premenstrual disorders are psychiatric or physical symptoms that occur during the luteal phase of the menstrual cycle and resolve after menstruation begins. These symptoms are cyclical and typically significant enough to disrupt normal daily activities.1 Women with premenstrual syndrome (PMS), the most common premenstrual disorder, can experience a wide range of symptoms, including bloating, swollen or tender breasts, fatigue, irritability, diarrhea, headache, back pain, anxiety, restlessness, or changes in appetite.2 , 3 Up to half of reproductive-age women are affected by PMS worldwide.4
The most severe form of PMS, premenstrual dysphoric disorder (PMDD), occurs in 5% to 8% of reproductive-age women and can significantly impact quality of life.1 , 5 , 6 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies PMDD as a depressive disorder that is characterized by periods of depressed mood, anxiety, irritability, and/or affective lability that occur in the week before menstruation.7 Women with PMDD experience higher lifetime rates of suicidal ideation and self-harm behaviors than women who do not have this condition.8 , 9
The etiology of PMS and PMDD are not well understood, but genetic factors and psychosocial factors such as stress are thought to be involved.2 , 3 , 10 Additional evidence has suggested a causal link between sensitivity to the fluctuations of certain hormones and neurotransmitters (e.g., progesterone, allopregnanolone, estrogen, serotonin, gamma-aminobutyric acid [GABA]) during the menstrual cycle and the development of these conditions.2 , 5 , 10 , 11 Some research has also found an overlap between depression and premenstrual symptoms, with depression being strongly associated with more severe PMS symptoms or the presence of PMDD.12 , 13 Other known risk factors include obesity, smoking, and pre-existing anxiety disorders.5
Diagnosis and Treatment
When diagnosing PMS, clinicians look for symptoms that are present during the 5 days before a menstrual cycle and that occur for at least three consecutive cycles. These symptoms must resolve within 4 days of the start of menses and be significant enough to interfere with daily activities.3 The process for diagnosing PMDD is similar, although the DSM-5 requires a person to have at least five out of a possible 11 symptoms, including one mood-related symptom. These symptoms, which are present during the luteal phase of the menstrual cycle and are minimal or absent during the follicular phase, must be severe enough to disrupt normal activities and present during at least two consecutive cycles.7 The diagnostic process will also typically involve ruling out other potential causes of symptoms (e.g., depression, anxiety, thyroid disorders).5
Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, citalopram, sertraline, and paroxetine, are the first-line treatment for the psychological and somatic symptoms of PMDD and severe cases of PMS. Hormone-based interventions (e.g., combination oral contraceptives) may provide relief from severe symptoms for some patients.5 , 10 , 11
Because PMDD has significant psychological impacts, researchers have investigated the use of interventions that can improve coping strategies or modify thoughts and behaviors. While the use of cognitive behavioral therapy (CBT) has been explored for this purpose in women with PMS and PMDD, the studies that have looked at the effects of CBT have had significant limitations.10 , 11 Dialectical behavior therapy, which was originally developed for people with borderline personality disorder, has been proposed as a potential alternative strategy for managing emotion dysregulation and lowering suicide risk in women with PMDD.14 , 15
Engaging in regular aerobic exercise, limiting stress, and maintaining healthy sleep habits during the premenstrual period can help manage symptoms, although these strategies are typically more successful for women with PMS than those with PMDD. Dietary supplementation with calcium carbonate has also been shown to offer some relief from PMS symptoms.10 , 11
Ongoing Research
PMS and PMDD encompass a range of episodic affective, physical, and behavioral symptoms, and more research is needed to understand their causes and develop effective management strategies. Questions remain about the specific mechanisms of hormone sensitivity in women with premenstrual disorders and how hormone fluctuations affect the symptoms of these disorders.
The variety of symptoms observed in women with PMDD, variations in the severity and timing of those symptoms, and inconsistent treatment responses (e.g., only about half of patients with PMDD respond to treatment with SSRIs16) suggest that PMDD may not be a singular disorder but a collection of subtypes with distinct symptom patterns. Identifying and characterizing these subtypes will lead to a better understanding of the underlying biological processes of PMDD and allow clinicians to provide more effective treatments for individual patients. In addition, neuroimaging studies are reporting changes in the volume and activity of certain brain regions in women with PMDD, which indicate that hormone fluctuations during the menstrual cycle may trigger maladaptive neural responses.16 - 18 The long-term impacts of using SSRIs for PMDD treatment need further study as well.
NIH Research Highlight
The Behavioral Endocrinology Branch at the National Institute of Mental Health (NIMH) supports research on the complex interactions between ovarian hormones and mood disorders. Researchers at NIMH employ metabolic, genomic, and neuroimaging strategies to identify potential risk factors and novel treatments for PMDD, as well as postpartum and perimenopausal depression.
Gamma-aminobutyric acid type A (GABA A ) receptors are prominent inhibitory neurotransmitter receptors in the central nervous system, and one proposed mechanism for PMDD pathogenesis involves a decrease in the sensitivity of these receptors to certain neuroactive steroids during the luteal phase of the menstrual cycle. NIMH-supported researchers are conducting a clinical trial that will track the plasma levels of GABAergic neuroactive steroids and the expression of GABA A receptor subunits during the luteal phase in women with and without PMDD. The researchers will also investigate how a low dose of the SSRI sertraline affects GABAergic neuroactive steroids and the expression of GABA A receptor subunits in women with PMDD. The study aims to better understand how these systems change across the menstrual cycle, explore potential pathways for the development of PMDD, and investigate the therapeutic mechanisms of SSRIs in people with this condition.19
- Liguori F, Saraiello E, Calella P. Premenstrual syndrome and premenstrual dysphoric disorder's impact on quality of life, and the role of physical activity. Medicina (Kaunas). 2023;59(11):2044. doi:10.3390/medicina59112044. https://pmc.ncbi.nlm.nih.gov/articles/PMC10673441/
- Gudipally PR, Sharma GK. Premenstrual Syndrome. StatPearls Publishing; 2023. Updated July 17, 2023. Accessed October 27, 2026. https://www.ncbi.nlm.nih.gov/books/NBK560698/
- Premenstrual syndrome (PMS). Office on Women's Health. Updated September 26, 2025. Accessed October 27, 2026. https://womenshealth.gov/menstrual-cycle/premenstrual-syndrome
- Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, Kaikhavandi S. Epidemiology of premenstrual syndrome (PMS)-a systematic review and meta-analysis study. J Clin Diagn Res. 2014;8(2):106-9. doi:10.7860/JCDR/2014/8024.4021. https://pmc.ncbi.nlm.nih.gov/articles/PMC3972521/
- Miller C, Carlson K. Premenstrual Disorders. StatPearls Publishing; 2026. Updated August 9, 2026. Accessed October 27, 2026. https://www.ncbi.nlm.nih.gov/books/NBK532307/
- Premenstrual dysphoric disorder (PMDD). Office on Women's Health. Updated September 26, 2025. Accessed October 27, 2026. https://womenshealth.gov/menstrual-cycle/premenstrual-syndrome/premenstrual-dysphoric-disorder-pmdd
- Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. June 2016. https://www.ncbi.nlm.nih.gov/books/NBK519697/
- Eisenlohr-Moul T, Divine M, Schmalenberger K, et al. Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry. 2022;22(1):199. doi:10.1186/s12888-022-03851-0. https://pmc.ncbi.nlm.nih.gov/articles/PMC8933886/
- Osborn E, Brooks J, O'Brien PMS, Wittkowski A. Suicidality in women with premenstrual dysphoric disorder: a systematic literature review. Arch Womens Ment Health. 2021;24(2):173-184. doi:10.1007/s00737-020-01054-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7979645/
- Hantsoo L, Epperson CN. Premenstrual dysphoric disorder: epidemiology and treatment. Curr Psychiatry Rep. 2015;17(11):87. doi:10.1007/s11920-015-0628-3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4890701/
- Ryu A, Kim TH. Premenstrual syndrome: a mini review. Maturitas. 2015;82(4):436-40. doi:10.1016/j.maturitas.2015.08.010. https://pubmed.ncbi.nlm.nih.gov/26351143/
- Padhy SK, Sarkar S, Beherre PB, Rathi R, Panigrahi M, Patil PS. Relationship of premenstrual syndrome and premenstrual dysphoric disorder with major depression: relevance to clinical practice. Indian J Psychol Med. 2015;37(2):159-64. doi:10.4103/0253-7176.155614. https://pmc.ncbi.nlm.nih.gov/articles/PMC4418247/
- Li H, Sarokhani M, Gilan MHS, Valizade R, Sayehmiri K. Prediction premenstrual syndrome (PMS) with anxiety, and depression in female students. BMC Psychiatry. 2025;25(1):794. doi:10.1186/s12888-025-07250-z. https://pmc.ncbi.nlm.nih.gov/articles/PMC12359940/
- Eisenlohr-Moul T. Premenstrual disorders: a primer and research agenda for psychologists. Clin Psychol. 2019;72(1):5-17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7193982/
- Oliveri A, Muir S, Mu E, Kulkarni J. Advancing psychological interventions for premenstrual dysphoric disorder: a dialectical behaviour therapy-informed treatment model. Aust N Z J Psychiatry. 2025;59(8):670-673. doi:10.1177/00048674251348370. https://pmc.ncbi.nlm.nih.gov/articles/PMC12375139/
- Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: from genes to GABA. Neurosci Biobehav Rev. 2023;149:105168. doi:10.1016/j.neubiorev.2023.105168. https://pmc.ncbi.nlm.nih.gov/articles/PMC10176022/
- Dubol M, Epperson CN, Lanzenberger R, Sundstrom-Poromaa I, Comasco E. Neuroimaging premenstrual dysphoric disorder: a systematic and critical review. Front Neuroendocrinol. 2020;57:100838. doi:10.1016/j.yfrne.2020.100838. https://pubmed.ncbi.nlm.nih.gov/32268180/
- Monteiro DC, Ramos CDS, Alves L, Cantilino A, Sougey EB. Functional and structural neuroimaging in premenstrual dysphoric disorder: a systematic review. J Psychiatr Res. 2024;175:205-210. doi:10.1016/j.jpsychires.2024.05.024. https://pubmed.ncbi.nlm.nih.gov/38744159/
- RePORTER project details: 1/2 allopregnanolone and dynamic GABA-A receptor plasticity in selective serotonin reuptake inhibitor responsive premenstrual dysphoric disorder. National Institutes of Health. Accessed October 27, 2026. https://reporter.nih.gov/search/hCp_OS1DyEuEiofqnv4CYQ/project-details/11380996